ARTICLE | Clinical News

Effient prasugrel: Phase II data

September 27, 2010 7:00 AM UTC

The double-blind, U.S. Phase II SWAP trial in 100 evaluable patients showed that switching to maintenance dosing with Effient plus aspirin from maintenance dosing with Plavix clopidogrel plus aspirin within 30-330 days following an ACS event met the primary endpoint of significantly reducing MPA at day 7 vs. patients who remained on Plavix therapy plus aspirin. Specifically, patients who switched to maintenance dosing with 10 mg Effient plus aspirin for 7 days, or a 60 mg Effient loading dose plus aspirin followed by 10 mg Effient plus aspirin for 6 days, both had an MPA of 41% vs. 55% for patients who remained on 75 mg Plavix plus aspirin for 7 days (p<0.0001 for both). Patients underwent a 10-14 day run-in of open-label 75 mg daily Plavix plus aspirin before randomization. Data were published in the Journal of the American College of Cardiology. ...